Sermorelin vs HGH: Key Differences

The question of sermorelin vs HGH comes down to one fundamental distinction: sermorelin tells your body to make more of its own growth hormone, while HGH (human growth hormone, also called somatropin) is the hormone itself, injected directly. Sermorelin is a synthetic analog of growth-hormone-releasing hormone (GHRH 1-29) that acts on the anterior pituitary to stimulate natural, pulsatile GH release. HGH bypasses that signaling and replaces the hormone outright. Those two approaches diverge in mechanism, regulatory status, the strength of the evidence behind them, and the legal rules around their use. This guide walks through each. It is educational information, not medical advice.

How does sermorelin work compared with HGH?

Sermorelin is a GHRH analog. It binds receptors on the pituitary gland and prompts it to secrete growth hormone, acting upstream rather than supplying GH directly. It works within the body’s existing feedback system: GH release is naturally pulsatile and is restrained by somatostatin and by IGF-1, so a GHRH-style signal still answers to those brakes. A review in Physiological Reviews describes this neuroendocrine loop in detail.

HGH is different. As recombinant growth hormone, it adds the hormone to the bloodstream regardless of what the pituitary is doing, which can suppress the body’s own production over time. Sermorelin also has a very short plasma half-life, roughly 11 to 12 minutes per a pharmacology review in JCSM Rapid Communications, consistent with its brief, pulse-preserving action. If you want a deeper primer on the molecule, see our overview of what sermorelin is.

What is the regulatory status of each?

This is where sermorelin and HGH separate most clearly, and it matters for anyone weighing the two.

HGH (somatropin) is FDA-approved, but only for narrow indications. Per the FDA-approved DailyMed label for Norditropin (somatropin), approved uses include pediatric growth failure from inadequate GH, short stature in Turner, Noonan, and Prader-Willi syndromes, children born small for gestational age without catch-up growth, idiopathic short stature, and replacement in adults with documented growth hormone deficiency. Anti-aging is not an approved use.

Sermorelin was previously FDA-approved as Geref (and Geref Diagnostic), but the branded product was discontinued in 2008. The FDA later determined, in a 2013 Federal Register notice, that it was not withdrawn for reasons of safety or effectiveness; the discontinuation was a business and manufacturing decision. The important nuance: that historical approval does not carry forward. The sermorelin available today is a compounded preparation, which is not FDA-approved. As the FDA explains in its compounding Q&A, compounded drugs do not undergo FDA premarket review, and the agency does not verify their safety, effectiveness, or quality before they are marketed.

Attribute	Sermorelin (compounded)	HGH / somatropin
What it is	GHRH (1-29) analog	Recombinant growth hormone
Mechanism	Stimulates the pituitary to release the body’s own GH	Supplies GH directly
Feedback loop	Works within natural pulsatile feedback	Bypasses/can suppress endogenous production
Plasma half-life	~11-12 minutes	Longer (varies by formulation)
FDA status today	Compounded; not FDA-approved	FDA-approved for specific indications only
Anti-aging use	Not an established or proven use	Not approved; distribution for anti-aging is illegal

Is it legal to use HGH for anti-aging?

No. In the United States, distributing or providing HGH for anti-aging, bodybuilding, or athletic enhancement is illegal. Under 21 U.S.C. 333(e), it is a federal felony to knowingly distribute, or possess with intent to distribute, human growth hormone for any use other than a disease or recognized medical condition authorized by the Secretary of Health and Human Services and prescribed by a physician. The statute defines “human growth hormone” as somatrem, somatropin, or an analogue of either. The penalty is up to 5 years in prison, rising to up to 10 years if a minor is involved. A 2005 JAMA commentary reached the same conclusion: anti-aging is not an authorized indication, so HGH cannot legally be distributed for it.

To be clear, Revive does not sell or provide HGH for anti-aging. This article compares the two categories for educational purposes only.

What does the evidence actually show?

Much of the popular interest in growth hormone traces to the Rudman 1990 NEJM trial, in which 12 men aged 61-81 with low IGF-1 received human growth hormone for 6 months and showed increased lean mass and decreased fat mass. Two cautions matter here. First, that is HGH data in older men, not sermorelin data. Second, even at the time, accompanying commentary warned against extrapolating those findings to general anti-aging use.

Later and larger evidence was more sobering. A 2007 systematic review in Annals of Internal Medicine pooled 18 unique randomized controlled trials (reported across 31 articles, 508 total participants) and found only small body-composition changes alongside higher rates of adverse effects, including edema, joint pain, carpal tunnel syndrome, and a trend toward glucose intolerance and diabetes. The authors concluded growth hormone cannot be recommended as an anti-aging therapy. Again, that is HGH evidence.

The honest bottom line for sermorelin: it lacks large randomized trials for adult anti-aging, and its long-term adult efficacy and safety are not established. Results reported for HGH should not be assumed to apply to sermorelin. Any benefits, body-composition changes, or timelines are provider-determined and variable, and individual results vary. If you are researching outcomes, our pages on sermorelin benefits and sermorelin before and after keep the same hedged framing.

How do the safety profiles compare?

Growth-hormone-pathway effects are not benign. The somatropin label contraindicates use in active malignancy and in acute critical illness, and excess GH and IGF-1, as seen in acromegaly, is associated with type 2 diabetes, cardiovascular disease, and cancer per a 2021 UK acromegaly population study. These are context for the GH pathway broadly, not sermorelin-specific outcomes.

For sermorelin itself, the original prescribing information reported that the most common treatment-related event was a local injection-site reaction (pain, swelling, or redness) in about 1 in 6 patients, with hypothyroidism noted in about 6.5% and a recommendation to monitor thyroid function, per RxList’s sermorelin acetate information. Those figures derive largely from pediatric and diagnostic use, not adult anti-aging, so they are label-reported context rather than expected Revive results. For more, see sermorelin side effects. Decisions to start, dose, or stop any therapy belong with a licensed provider.

Frequently asked questions

What is the main difference between sermorelin and HGH?

Sermorelin is a GHRH analog that stimulates the pituitary to release the body’s own growth hormone within its natural feedback loop, while HGH (somatropin) is recombinant growth hormone injected directly. They also differ in regulatory status: HGH is FDA-approved for specific medical indications, whereas the sermorelin available today is compounded and not FDA-approved. This is educational information, not medical advice.

Is sermorelin FDA-approved?

Not currently. Sermorelin was once FDA-approved as Geref, but that branded product was discontinued in 2008 for business and manufacturing reasons (not safety or effectiveness, per a 2013 FDA Federal Register notice). The sermorelin used today is a compounded preparation, which is not FDA-approved; the FDA has not evaluated it for safety, quality, or efficacy.

Is it legal to take HGH for anti-aging?

No. Under 21 U.S.C. 333(e), distributing human growth hormone for any use not authorized by the Secretary of Health and Human Services, including anti-aging, bodybuilding, and athletic enhancement, is a federal felony punishable by up to 5 years in prison (up to 10 if a minor is involved). HGH is FDA-approved only for specific deficiency and medical conditions.

Does sermorelin produce the same body-composition results as HGH?

That cannot be assumed. The well-known body-composition findings come from HGH trials in specific populations, such as the Rudman 1990 study in men aged 61-81. Sermorelin lacks large randomized trials for adult anti-aging, and its long-term efficacy and safety in adults are not established. Individual results vary, and any outcomes are provider-determined.

What are the reported side effects of sermorelin?

Per the original prescribing information, the most common treatment-related event was a local injection-site reaction (pain, swelling, or redness) in about 1 in 6 patients, with hypothyroidism reported in about 6.5% and a recommendation to monitor thyroid function. Other reported effects included headache, flushing, and dizziness. These figures come largely from pediatric and diagnostic use. A licensed provider can review your individual situation.

Why is sermorelin only available as a compounded product?

Because the FDA-approved branded version (Geref) was discontinued in 2008, no FDA-approved finished sermorelin drug remains on the market. Today it is prepared by compounding pharmacies. The FDA does not review compounded drugs for safety, effectiveness, or quality before they are marketed, so compounded sermorelin is not FDA-approved.